New Hampshire data mining law overturned

13 May 2007

The US State of New Hampshire has announced that it will appeal a federal trial court decision, that a state law which banned firms from "data mining" by selling, using or distributing patients' prescription drug information, was unconstitutional. Federal Judge Paul Barbadoro ruled that the law violates the the US Constitution's First Amendment and "restricts constitutionally protected speech."

New Hampshire Governor John Lynch (Democrat) approved legislation last year that made New Hampshire the first state to restrict drugmakers from having access to information that identifies physicians' prescribing choices.

IMS Health and Verispan, two of the major US analysts of medical data, filed a complaint in a US District Court. The plaintiffs said the law "violated free speech rights, endangered public health and impeded research." The New Hampshire case was that: "our primary argument was that the transmission of data was not speech."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight